Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Side-effects news

Show

From To
Marijuana Could Be Huge for Treating HIV

From inflammation to lowering levels of the virus itself, a current study hopes to demystify pot's benefits for those living with HIV.

Published
17 November 2017
From
VICE
Gilead’s Updated Version of Tenofovir Performs Well Among Blacks With HIV

Compared with the older tenofovir, called TDF, the new one, TAF, suppressed the virus as well and offered bone, kidney and lipid benefits.

Published
18 October 2017
From
Poz
Impact of side-effects on retention in HIV care is underestimated, African study suggests

The impact of drug side-effects on retention in HIV care is probably being underestimated, according to an interview-based study of people taking antiretroviral treatment and

Published
10 October 2017
By
Keith Alcorn
HIV Regimen Switch May Contribute to Weight Gain

According to results of a study presented at IDWeek 2017, an increase in body weight is common in HIV patients who are switched from efavirenz/tenofovir disoproxil fumarate/emtricitabine (EFV/TDF/FTC) to an integrase strand transfer inhibitor.

Published
09 October 2017
From
Monthly Prescribing Reference
BHIVA response to BMJ article on ART in pregnant women living with HIV

We do not support recommendations of "ART in pregnant women living with HIV: a clinical practice guideline" (BMJ, 11/9/17). Other systematic reviews and numerous observational studies show tenofovir to be safe in HIV in pregnancy.

Published
25 September 2017
From
BHIVA
New recommendations aim to help pregnant women with HIV make informed choices

New recommendations on antiretroviral drugs for pregnant women living with HIV can help women make more informed choices about benefits and harms, say a panel of international experts in The BMJ today. The panel recommend older drug combinations instead of the most widely used regimens to help reduce the risk of premature birth and neonatal death - which almost all women said they were extremely keen to avoid.

Published
12 September 2017
From
EurekAlert
Lipids improved by switching from ritonavir to cobicistat as a booster for darunavir

Switching from ritonavir to cobicistat is associated with significant improvements in cholesterol and triglyceride levels for people with dyslipidaemia, investigators from Spain report in HIV Medicine. Ritonavir was replaced

Published
06 September 2017
By
Michael Carter
Case reports of severe dolutegravir-related depression

Severe depression can be a side-effect of treatment with the anti-HIV drug dolutegravir. In HIV Medicine, clinicians from the Netherlands report two cases of rapid onset of

Published
05 September 2017
By
Michael Carter
Taking dolutegravir in the morning may avert insomnia

Italian doctors say that sleeplessness after taking the integrase inhibitor dolutegravir occurred much less often when their patients took their dose of the drug in

Published
31 August 2017
By
Keith Alcorn
Dutch study finds out whether gay men prefer daily or on-demand PrEP

In Europe, whether through national programmes or in trials, people are more often than not being given the choice of taking pre-exposure prophylaxis (PrEP) daily or intermittently

Published
28 July 2017
By
Gus Cairns
← First12345...78Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.